Press Release / May 07, 2026
Hovione and IDC Intranasal Drug Delivery Platform Available for Commercial Partnerships
Its lead single-use nasal dry powder device now available for commercial partnerships
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Its lead single-use nasal dry powder device now available for commercial partnerships
Commitment to partnership and joint innovation for cell and gene therapies
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.